Share Class
GB00BMGLBK75
A global, high-conviction equity fund for long-term investors
- A fund focusing on high quality companies with sustainable profitability, “compounders” that reinvest their earnings for future growth
- A concentrated, low turnover portfolio of high-conviction names seeking to achieve steady capital growth over the long term
- An investment process based on rigorous fundamental analysis, quantitative screening, and a socially responsible investment approach
Key documents
Asset Allocation
Equities94.4 %
Other5.6 %
Data as of: 31 Oct 2025.
Risk Indicator
1
2
3
4
5
6
7
Lowest risk
Highest risk
Recommended Minimum Investment Horizon
5 years
Cumulative Performance since launch
Cumulative Performance 10 YearsCumulative Performance 5 YearsCumulative Performance 3 YearsCumulative Performance 12 Months
+ 74.6 %
-
+ 45.3 %
+ 39.7 %
- 2.1 %
To 04/12/2025
Calendar Year Performance 2015Calendar Year Performance 2016Calendar Year Performance 2017Calendar Year Performance 2018Calendar Year Performance 2019Calendar Year Performance 2020Calendar Year Performance 2021Calendar Year Performance 2022Calendar Year Performance 2023Calendar Year Performance 2024
-
-
-
-
-
+ 23.1 %
+ 22.6 %
- 19.0 %
+ 21.0 %
+ 17.6 %
Net Asset Value
1.75 £
Asset Under Management
85 M £
Net Equity Exposure31/10/2025
94.4 %
Data as of: 31 Oct 2025.
Data as of: 4 Dec 2025.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).
The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.
FP Carmignac Global Equity Compounders fund performance
Take a look at the Fund's performance supported by our Fund managers’ market commentary and strategy insight.
Our monthly comments
Data as of: 28 Nov 2025.Fund management team
![[Management Team] [Author] Denham Mark](https://carmignac.imgix.net/uploads/NextImage/0001/18/%5BManagement-Team%5D-Denham-Mark.png?auto=format%2Ccompress&fit=fill&w=3840)
Mark DENHAM
Head of Equities, Fund Manager
![[Management Team] [Author] Ejikeme Obe](https://carmignac.imgix.net/uploads/NextImage/0001/18/%5BManagement-Team%5D-Ejikeme-Obe.png?auto=format%2Ccompress&fit=fill&w=3840)
Obe EJIKEME
Fund Manager, Analyst
Performance commentary
- In November, the Fund delivered a negative absolute and relative performance.
- The relative underperformance was mainly driven by the technology sector as November marked the sharpest tech-led correction since April.
- This downturn was driven by elevated valuations and bubble concerns, compounded by fading expectations for Fed rate cuts mid-month.
- Strong compounders such as Microsoft and ServiceNow were also caught in the selloff, penalized by macro-driven sentiment and AI-related execution concerns, despite solid fundamentals and strong prior performance.
- Conversely, after several months of softness, our healthcare holdings delivered strong absolute returns. Eli Lilly led the way, surging about 25% on the back of robust EPS and revenue growth.
- Similarly, our consumer staples positions, including Colgate and L’Oréal, posted solid gains, highlighting their resilience amid market volatility.
Outlook strategy
- Our macroeconomic framework continues to advocate a defensive positioning, as valuation remains a key concern at the overall market level.
- During the month, we made several portfolio adjustments fully exiting our positions in Danaher and Eli Lilly following their strong performance.
- We initiated new positions in Arista Networks and Doximity after recent weakness, as both companies demonstrate solid growth prospects and robust balance sheets.
- Defensive sectors are trading at their most attractive relative valuations in nearly two decades, offering resilience and diversification benefits should growth expectations disappoint.
- In the current environment, earnings visibility is likely to be increasingly rewarded. We therefore maintain a disciplined stance, limiting exposure to cyclical sectors in favour of quality.
- Our portfolio remains positioned to benefit from secular growth trends such as AI and digital transformation, while maintaining the flexibility and discipline needed to navigate an uncertain macro backdrop.
Performance Overview
Data as of: 4 Dec 2025.Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).
Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Source: Carmignac at 06/12/2025
FP Carmignac Global Equity Compounders Portfolio overview
Below is an overview of the composition of the portfolio.
Geographical Breakdown
Data as of: 31 Oct 2025.| North America | 62.4 % |
| Europe | 37.6 % |
To Access the weekly view
Key figures
Below are the key figures for the Fund, which will give you a clearer idea of the Fund's management and equity positioning.
Exposure Data
Data as of: 31 Oct 2025.Equity Investment Weight94.4 %
Net Equity Exposure94.4 %
Number of Equity Issuers41
Active Share77.8 %
To Access the weekly view
The strategy in a nutshell
Discover the Fund’s main features and benefits through the words of the Fund Managers.
Fund Management Team
Mark DENHAM
Head of Equities, Fund Manager
Obe EJIKEME
Fund Manager, Analyst
FP Carmignac Global Equity Compounders is an intergenerational Fund that focuses on high-quality companies to help investors build capital not only for themselves, but also for future generations.
Articles that may interest you
Strategies insights • 16 October 2025 • English
FP Carmignac Global Equity Compounders: Letter from the Fund Managers - Q3 2025
3 minute(s) read
Strategies insights • 14 October 2025 • English
Rethinking reinvestment: Unlocking the true power of compounding
Strategies insights • 14 July 2025 • English
FP Carmignac Global Equity Compounders: Letter from the Fund Managers - Q2 2025
3 minute(s) read
Did you enjoy the fund page?
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performance is shown net of fees (excluding any subscription fees payable to the distributor). Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.
Market environment